Objective: Non-alcoholic fatty liver disease (NAFLD) is associated with abnormalities in basal glucose and free fatty acid (FFA) metabolism, multi-organ insulin resistance and alterations in lipoprotein kinetics. These metabolic outcomes can be evaluated in vivo by using stable isotopically labeled tracer methods. An understanding of the reproducibility of these measures is necessary to ensure adequate statistical power in studies designed to evaluate metabolic function in subjects with NAFLD. Methods: We determined the degree of intra-individual variability of skeletal muscle, adipose tissue, and hepatic insulin sensitivity and basal plasma glucose, FFA, and very-low-density lipoprotein triglyceride and apolipoprotein B-100 (apoB-100) kinetics in eight obese subjects with NAFLD (age: 44 ± 3 years; body mass index: 38.2 ± 1.7 kg m À2 ; intrahepatic triglyceride content: 24.5±3.9%), by using the hyperinsulinemic-euglycemic clamp technique and stable isotope-labeled tracer methods and mathematical modeling on two separate occasions B2 months apart. Results: The intra-individual variability (coefficient of variation) ranged from 6% for basal glucose production to 21% for insulinstimulated glucose disposal (percentage increase from basal). We estimated that a 25% difference in any outcome measure can be detected with a sample size of p8 subjects for paired studies and p15 subjects per group for unpaired studies, assuming an a value of 0.05 and a b value of 0.20 (that is, 80% power).
Introduction
Non-alcoholic fatty liver disease (NAFLD) comprises a spectrum of liver abnormalities, 1 characterized by the excessive accumulation of triglyceride (TG), with or without inflammation and fibrosis. 2 The presence of NAFLD is strongly associated with the presence of metabolic abnormalities that are risk factors for coronary heart disease, particularly alterations in glucose and fatty acid kinetics, insulin action and hepatic lipoprotein metabolism. [3] [4] [5] Therefore, assessment of these metabolic functions is an important outcome measure in NAFLD research. Substrate metabolism and multi-organ insulin sensitivity can be reliably evaluated in vivo in human subjects. A twostage hyperinsulinemic-euglycemic clamp procedure combined with stable isotope-labeled tracer infusion can be used to evaluate insulin sensitivity in skeletal muscle, adipose tissue and liver. 6 Stable isotope-labeled tracer techniques can also be used to assess basal glucose, free fatty acid (FFA), very-low-density lipoprotein (VLDL) TG and VLDL-apolipoprotein B-100 (apoB-100) metabolism. 7, 8 These types of studies are usually conducted in small numbers of subjects because they are expensive, require sophisticated analytical techniques and are burdensome for study participants. [9] [10] [11] [12] [13] [14] Therefore, an understanding of the reproducibility of these metabolic outcome measures is necessary to be able to design studies that contain the appropriate number of subjects needed to detect an effect of an intervention or differences between study groups. This issue might be particularly important in obese subjects with NAFLD, because of fluctuations in liver biochemistries, 15, 16 which could represent an underlying variability in metabolic function.
The purpose of the present study was to determine the reproducibility and intra-individual variability of skeletal muscle, adipose tissue, and hepatic insulin sensitivity and basal glucose, FFA, VLDL-TG and VLDL-apoB-100 kinetics in obese subjects with NAFLD. Stable isotope tracer infusion studies were performed at baseline and repeated about 2 months later. This information was used to provide estimates of minimum differences needed to detect a statistically significant effect on selected metabolic outcomes for any given sample size for both paired (longitudinal) and unpaired (cross-sectional) study designs.
Materials and methods

Subjects
Eight obese subjects with NAFLD (intrahepatic triglyceride (IHTG) content 410%) participated in this study (44 ± 3 years old, six women and two men; Table 1 ). All subjects completed a comprehensive medical evaluation, which included a 2-h oral glucose tolerance test. Body fat mass and fat-free mass were determined by using dual-energy X-ray absorptiometry (Delphi-W densitometer, Hologic, Waltham, MA, USA), and IHTG content was measured by using proton magnetic resonance spectroscopy (Siemens, Erlanger, Germany) as previously described. 17 Potential participants who smoked cigarettes, consumed X20 g per day of alcohol, had severe hypertriglyceridemia (4300 mg per 100ml), diabetes or IHTG content p10% were excluded. All subjects had been weight-stable (p2% change in weight) and sedentary (exercise o1 h per week) for at least 3 months before enrollment. Subjects provided their written informed consent before participating in this study, which was approved by the Human Research Protection Office of Washington University School of Medicine.
Experimental protocol
Each subject underwent a 9.5 h, two-stage hyperinsulinemiceuglycemic clamp procedure, in conjunction with stable isotope tracer infusions, to evaluate adipose tissue, skeletal muscle and hepatic insulin sensitivity, and a 12-h isotope infusion study in conjunction with mathematical modeling to determine VLDL-TG and VLDL-apoB-100 kinetics B1 week apart. Both studies were repeated B2 months later. Subjects were instructed to maintain their usual dietary and physical activity habits during this period. Blood samples were obtained immediately before starting the tracer infusion and every 10 min during the final 30 min of the basal period, and stages 1 and 2 of the clamp procedure. To determine plasma glucose concentration, blood was collected in tubes containing heparin; plasma was separated by centrifugation and analyzed immediately. All other blood samples were collected in chilled tubes containing sodium EDTA. Samples were placed immediately Total plasma TG and VLDL-TG concentrations were determined with a colorimetric enzymatic kit (Sigma Chemicals, St Louis, MO, USA) and VLDL-apoB-100 concentration with a turbidimetric immunoassay (Wako Pure Chemical Industries, Osaka, Japan).
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Substrate enrichments. The tracer-to-tracee ratios (TTRs) of plasma glycerol, glucose, palmitate and leucine, the TTRs of glycerol and palmitate in VLDL-TG, and the TTR of leucine in VLDL-apoB-100 were determined by using gas chromatography-mass spectrometry (Agilent Technologies/HP 6890 Series GC System-5973 Mass Selective Detector, Hewlett-Packard), as described previously. [18] [19] [20] [21] [22] The heptafluorobutyryl derivative was formed for the analysis of plasma glucose and glycerol in plasma and VLDL-TG, the tertiary-butyldimethylsilyl derivative was prepared for plasma leucine, and the N-heptafluorobutyryl n-propyl ester derivative was used for leucine in VLDL-apoB-100. Plasma free palmitate and palmitate in VLDL-TG were analyzed as methyl esters.
Calculations
Insulin sensitivity. The two insulin infusion rates during the clamp procedure were chosen to evaluate adipose tissue insulin sensitivity (low-dose insulin infusion to submaximally suppress lipolysis of adipose tissue TG), hepatic insulin sensitivity (low-dose insulin infusion to submaximally suppress hepatic glucose production), and skeletal muscle insulin sensitivity (high-dose insulin infusion to adequately stimulate muscle glucose uptake). 6 
VLDL kinetics
The fractional turnover rate (FTR) of VLDL-TG was determined by fitting the TTR time-courses of free glycerol in plasma and glycerol in VLDL-TG to a compartmental model. 22 We have previously shown that plasma concentrations of VLDL-TG and VLDL-apoB-100 remain constant during the time-frame of our experiments. 18, 23 The rate of VLDL-TG secretion, which represents the amount of VLDL-TG secreted by the liver per unit of plasma, was calculated by multiplying the FTR by the steady-state plasma concentration of VLDL-TG. The plasma clearance rate of VLDL-TG, which is an index of the removal efficiency of VLDL-TG from plasma, was calculated as FTR times volume of distribution; VLDL-TG volume of distribution was assumed to equal plasma volume (calculated as 55 ml per kg of fat-free mass) because VLDL particles are essentially confined into the plasma compartment. 24 The relative contribution of systemic plasma fatty acids (that is, FFA from the systemic circulation that are taken up by the liver and directly incorporated into VLDL-TG) to total VLDL-TG production was determined by the degree of isotopic dilution upon fitting the palmitate TTR in plasma and VLDL-TG to a compartmental model, 18, 19, 22 and was used to calculate the relative contribution of non-systemic fatty acids by subtraction. Non-systemic fatty acids are derived from pools of fatty acids that are not labeled with [2,2-2 H 2 ]palmitate during the infusion period, including fatty acids released from pre-existing, slowly turning over lipid stores in the liver and tissues draining directly into the Variability of metabolic kinetics in NAFLD F Magkos et al portal vein, fatty acids resulting from lipolysis of plasma lipoproteins that are taken up by the liver, and fatty acids derived from hepatic de novo lipogenesis. 25 The FTR of VLDL-apoB-100 was calculated by fitting the TTR time-courses of free leucine in plasma and leucine in VLDLapoB-100 to a compartmental model. 18, 19 Hepatic secretion and plasma clearance rates of VLDL-apoB-100 were calculated based on plasma VLDL-apoB-100 concentration and VLDLapoB-100 FTR, as described above for VLDL-TG. The kinetic parameters of VLDL-apoB-100 are indices of the secretion and plasma clearance rates of VLDL particles, because each VLDL particle contains a single molecule of apoB-100. 26 Statistical analysis and reproducibility statistics All data sets were normally distributed according to the Kolmogorov-Smirnov criteria. Results from the two study days were compared with Student's paired, two-tailed t-test. Summary data are presented as means±s.e.m. A P-valuep0.05 was considered statistically significant. Reproducibility statistics (that is, change in the mean, total error and typical error) and sample size estimations were computed according to Hopkins. 27 The change in the mean represents the average difference between the paired individual values obtained in the two studies; it consists of a random change component and a systematic (non-random) change component. The 95% confidence interval (CI) of the change in the mean was calculated to assess the absence (when the 95% CI spans zero) or presence (when the 95% CI does not include zero) of a systematic change. The total error of measurement, which reflects total measurement variability, was assessed by the intra-individual coefficient of variation (CV), calculated as the individual s.d. for the values obtained on the two different study days divided by the mean of the two values, and expressed as percent. We have previously evaluated the analytical variability of substrate concentration and enrichment measurements and found that almost all (492%) of the total measurement variability is of biological origin. 18 The typical error of measurement, which reflects within-subject variability and includes all sources of error, was calculated as the s.d. of the change in the mean divided by the square root of 2, and expressed as percent; the typical error was used to estimate the required sample size as a function of the minimum detectable difference for key outcome variables, assuming a ¼ 0.05 and b ¼ 0.20 (that is, 80% power), for both paired and unpaired experimental designs.
Results
Subject characteristics and basal metabolic profile on the two study days Body weight and body mass index, body fat, fat-free mass and IHTG content were not different between the two study days (Table 1) . Basal plasma glucose (5.5±0.2 and 5.7 ± 0.3 mmol l
À1
, P ¼ 0.272), insulin (25 ± 2 and 24 ± 3 mU l Reproducibility of basal substrate kinetics and insulin sensitivity No significant differences were detected between the first and second studies in mean basal glucose and palmitate Ra, insulin-mediated suppression of glucose Ra and palmitate Ra and stimulation of glucose Rd, VLDL-TG and VLDL-apoB-100 secretion and clearance rates, or the relative contribution of non-systemic fatty acids to VLDL-TG production ( Table 2) . In all cases, the 95% CI for the change in the mean included zero, indicating the absence of Abbreviations: apoB-100, apolipoprotein B-100; CI, confidence interval; CV, coefficient of variation; Ra, rate of appearance; Rd, rate of disappearance; TG, triglyceride; VLDL, very-low-density lipoprotein.
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Sample size estimations for minimum detectable differences An estimate of the minimum number of subjects needed to detect significant changes in key outcome variables in a paired study design, assuming a ¼ 0.05 and b ¼ 0.20 (power ¼ 80%), was used to construct a nomogram (Figure 1 ).
Total sample size (experimental plus control subjects) required for a cross-sectional study design with two groups can be derived by multiplying the number of subjects required for the paired design by four. The sample size per group needed to detect significant differences between two groups (containing an equal number of subjects/group) in a cross-sectional study design can be calculated by multiplying the number of subjects required for the paired study design by two. Sample size requirements for selected differences in mean values, for a paired study design and for an unpaired study design with two groups, are given in Table 3 .
Discussion
In this study, we examined the reproducibility of evaluating basal substrate kinetics and organ-specific insulin sensitivity in obese subjects with NAFLD. The variability in our outcome measures includes both technical (variability in performance of the clamp procedure and the isotope infusions and sample analyses) and physiological (variability in metabolic function) factors. Our results indicate that metabolic function in obese subjects is stable and the intraindividual variability (that is, CV) in these metabolic outcome measures ranges from 6 to 21%. In general, the variability was less for straightforward outcome measures that involved a constant infusion of tracer and calculations based on standard isotope tracer dilution principles (for example, basal glucose and palmitate Ra) than for more complex measures that involved manipulating the physiological environment (for example, organ insulin sensitivity) or based on bolus tracer injection with mathematical modeling (for example, VLDL-TG kinetics). Nevertheless, for all metabolic variables examined, we found that a 25% difference in any outcome measure can be detected with a sample size of p8 subjects for paired studies and p15 Figure 1 Minimum number of subjects needed to detect significant differences in basal plasma glucose, palmitate and VLDL kinetics, and hepatic (glucose Ra suppression by low-dose insulin), adipose tissue (palmitate Ra suppression by low-dose insulin) and skeletal muscle (glucose Rd stimulation by high-dose insulin) insulin sensitivity assuming a ¼ 0.05 and b ¼ 0.20 (power ¼ 80%) in a paired study design. The sample size/group needed to detect significant differences between two groups in a cross-sectional study design can be calculated by multiplying the number of subjects required for the paired study design by two. Ra, rate of appearance; Rd, rate of disappearance; VLDL, very-low-density lipoprotein; TG, triglyceride; apoB-100, apolipoprotein B-100. Abbreviations: apoB-100, apolipoprotein B-100; Ra, rate of appearance; Rd, rate of disappearance; TG, triglyceride; VLDL, very-low-density lipoprotein.
Variability of metabolic kinetics in NAFLD F Magkos et al subjects per group for unpaired studies, assuming an a value of 0.05 and a b value of 0.20 (that is, 80% power). However, even though significant differences in some metabolic outcome variables might be detected with only few subjects, both within and between groups, such small studies (for example, fewer than five subjects) would not likely generate convincing conclusions.
Our results demonstrate that multi-organ insulin sensitivity is stable over 2 months in obese persons with NAFLD. Furthermore, we found that the intra-individual variability of insulin action in liver (suppression of glucose Ra) and adipose tissue (suppression of palmitate Ra) (CVs of 10-15%) was smaller than the variability of insulin action in skeletal muscle (stimulation of glucose Rd) (CV of 21%), possibly because the dose of infused insulin resulted in near maximum suppression of glucose production and lipolytic rate, but was not adequate to maximally stimulate muscle glucose uptake. 28 Our estimates compare favorably with those from previous studies, which only evaluated the variability in whole-body insulin sensitivity, determined as the glucose infusion rate needed to maintain euglycemia during insulin infusion without isotope tracers, and reported CVs between 3 and 35%. [29] [30] [31] [32] [33] [34] [35] [36] The results from our study demonstrate that only a small number of subjects are needed to detect clinically relevant improvements in insulin sensitivity. Moderate (B10%) diet-induced weight loss and thiazolidinedione therapy increase skeletal muscle insulin sensitivity (that is, insulin-stimulated increase in glucose disposal) by 25-75%, 12,13,37-39 hepatic insulin sensitivity (that is, insulin-mediated suppression in glucose production) by 40-125%, 37, 40, 41 and adipose insulin sensitivity (that is, insulin-mediated suppression of lipolysis) by 30-45%. 42, 43 Our data suggest that a 25% improvement or a betweengroup difference in skeletal muscle insulin sensitivity can be detected in obese subjects with NAFLD with only six subjects in a paired design and eleven subjects per group in a two-arm unpaired study at the 5% level of significance with 80% power; fewer subjects would be needed to detect a 25% improvement or a between-group difference in hepatic and adipose tissue insulin sensitivity. We found that the intra-individual variability of basal VLDL-TG and VLDL-apoB-100 kinetics in our obese subjects with NAFLD ranged from 9 to 15%, which is similar to values reported in studies conducted in healthy lean men 18 and premenopausal women. 44, 45 Therefore, even though our subjects had increased IHTG content, which is associated with an increase in VLDL-TG secretion rate, 4,10,46 the reproducibility in VLDL kinetics was not different than that observed in subjects who have a normal amount of IHTG. Our estimates demonstrate that few subjects are needed to detect the clinically relevant effects of moderate (B10%) diet-induced weight loss or treatment with niacin, fenofibrate, or atorvastatin, which cause a 35-65% change in VLDL-TG secretion and clearance rates, and a 25-60% change in VLDL-apoB-100 secretion and clearance rates. 14, 19, [47] [48] [49] In conclusion, our data demonstrate that longitudinal and cross-sectional differences in basal substrate kinetics and organ-specific insulin sensitivity, assessed by using sophisticated in vivo metabolic research techniques, can be detected with acceptable statistical power in small numbers of obese subjects with NAFLD. This information will be useful in designing studies that investigate metabolic function in subjects with NAFLD. In addition, these data illustrate the potential efficiency in conducting studies in small numbers of subjects to evaluate the metabolic effects of novel interventions, before embarking on large multicenter studies to detect effects on clinical outcomes.
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